Cannabigerol (CBG) is gaining attention as another potentially therapeutic cannabinoid found in cannabis. A 2026 survey published in the Journal of Psychoactive Drugs examined how 239 people were using CBG or its acidic precursor CBGA, what conditions they were treating, and how effective they believed it was.
The most commonly reported uses were insomnia or disturbed sleep (62%), inflammatory chronic pain (44%), anxiety (33%), episodic pain (29%), and neuropathic chronic pain (28%). Participants generally reported that CBG/CBGA improved their symptoms, with responses ranging from “slightly improves” to “much improves.”
Users typically reported taking about 10–12 mg of CBG. After oral use, effects were commonly felt within 15–60 minutes and were reported to last approximately 4–6 hours. The researchers said these findings can help guide future human clinical trials investigating CBG while providing some of the first detailed information on how people are already using it.
“Cannabigerol (CBG) and the acidic form of CBG (cannabigerolic acid, CBGA) are becoming increasingly more available and popular, with pre-clinical rodent research suggesting these compounds have an array of therapeutic effects. However, there have been few clinical trials or surveys examining their effects in humans.
We conducted a survey of 239 CBG/CBGA users to assess the medical conditions they use CBG/CBGA to manage, as well as their perceived efficacy and satisfaction with CBG/CBGA for managing these conditions. Participants also reported on their typical use patterns (e.g. typical dose), their perceived time to feel effects, and duration of those effects.
The top five conditions participants reported using CBG/CBGA to manage were insomnia/disturbed sleep (62%), inflammatory chronic pain (44%), anxiety (33%), episodic pain (29%), and neuropathic chronic pain (28%), with participants generally reporting that CBG/CBGA “slightly improves” to “much improves” their symptoms. Participants reported typically using a dose of 10-12 mg of CBG and they indicated that they feel effects within 15-60 min of oral ingestion and that these effects persist for 4-6 h.
These findings will help inform consumers of CBG as well as researchers designing clinical trials to investigate the effects of CBG on humans in a more objective manner.”
https://pubmed.ncbi.nlm.nih.gov/42741890
“The current survey study indicates that CBG/CBGA are being used to treat a variety of medical conditions with the most commonly reported being insomnia/disturbed sleep, inflammatory chronic pain, anxiety, episodic pain, and neuropathic chronic pain, with participants generally reporting “slight improvement” to “much improvement” in symptoms and being “somewhat satisfied” to “mostly satisfied” with the efficacy. Side effects reported were minimal and benign. Based on the current findings, we recommend researchers consider using ecologically valid doses in the range of 10–15 mg, allow 30–60 min for orally administered CBG products to take effect, and expect these effects to last between 4 and 6 h.”
https://www.tandfonline.com/doi/full/10.1080/02791072.2026.2727651